Cancer cells have the capacity to avoid or to adulterate the suppressive influence of the TGFβ pathway, either through the inactivation of principal components of the pathway (by mutation or other mechanisms) or by downstream alterations that disable just the tumor-suppressive arm of this pathway. The gene discussed is TGFB1; the disease is neoplasm.